BiotechTube

Bmab 1000 + Prolia®

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Postmenopausal Women With Osteoporosis

Conditions

Postmenopausal Women With Osteoporosis

Trial Timeline

May 24, 2022 → Jun 12, 2024

NCT ID
NCT05345691

About Bmab 1000 + Prolia®

Bmab 1000 + Prolia® is a phase 3 stage product being developed by Biocon for Postmenopausal Women With Osteoporosis. The current trial status is completed. This product is registered under clinical trial identifier NCT05345691. Target conditions include Postmenopausal Women With Osteoporosis.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (2)

NCT IDPhaseStatus
NCT05345691Phase 3Completed
NCT05323708Phase 1Completed

Competing Products

20 competing products in Postmenopausal Women With Osteoporosis

See all competitors
ProductCompanyStageHype Score
ENZ215 + ProliaAlkem LaboratoriesPhase 3
77
teriparatide + teriparatide + Placebo + Calcium Supplement + Vitamin D SupplementEli LillyPhase 3
77
teriparatide 20 micrograms/day subcutaneous + salmon calcitonin 100 IU/day subcutaneousEli LillyPhase 3
77
CT-P41 + US-licensed ProliaCelltrionPhase 3
77
LetrozoleChugai PharmaceuticalPhase 2
52
Eldecalcitol soft capsulesChugai PharmaceuticalPre-clinical
23
LetrozoleChugai PharmaceuticalPhase 2
52
LetrozoleChugai PharmaceuticalPhase 2
52
menatetranone + alfacalcidolEisaiPhase 3
77
teriparatide + raloxifene + placeboEli LillyPhase 3
77
Teriparatide + Strontium ranelateEli LillyApproved
85
teriparatideEli LillyApproved
85
LY333334 + PlaceboEli LillyPhase 1
33
Teriparatide + RaloxifeneEli LillyApproved
85
teriparatide + aldrenodate + raloxifeneEli LillyApproved
85
LAE102 SC + Placebo SC + LAE102 IV + Placebo IVEli LillyPhase 1
33
BlosozumabEli LillyPhase 1
33
BlosozumabEli LillyPhase 1
33
Arzoxifene + RaloxifeneEli LillyPhase 3
77
teriparatide + raloxifene HCl + placeboEli LillyApproved
85

Other Products from Biocon

Stelara + Bmab1200Phase 3
77
EQ001 + EQ001 PlaceboPhase 3
77
Itolizumab + EQ001 PlaceboPhase 3
77
Humira 40 MG in Prefilled Syringe + Hulio 40 MG in Prefilled Syringe / Humira 40 MG in Prefilled SyringePhase 3
77
PERT-IJS plus trastuzumab, carboplatin and docetaxel + Perjeta plus trastuzumab, carboplatin and docetaxelPhase 3
77